Munich’s mbiomics closes 30 million euros to develop a live bacterial product

Munich-based texbio is developing a live bacterial product designed to boost immune checkpoint inhibitor response in advanced melanoma with a Phase 1B study scheduled for 2027. mbiomics GmbHtexbio, a Munich-based developer of microbiome-based therapeutics, has closed its third and final…











